<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>REGIMEX- benzphetamine hydrochlorideÂ tabletÂ </strong><br>Wraser Pharmaceuticals<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"><span class="Bold">Regimexâ„¢</span>  (Benzphetamine hydrochloride) tablets contain the <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectic</span> agent benzphetamine hydrochloride. Benzphetamine hydrochloride is a white crystalline powder readily soluble in water and 95% ethanol. The chemical name for benzphetamine hydrochloride is <span class="Italics">d</span>-N,Î±-Dimethyl-N-(phenylmethyl)-benzeneethanamine hydrochloride and its molecular weight is 275.82.</p>
<p>The structural formula (dextro form) is represented below:</p>
<div class="Figure"><img alt="benzphetamine hydrochloride" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1a5d7233-4453-42a5-8144-a4276db39660&amp;name=1a5d7233-4453-42a5-8144-a4276db39660-01.jpg"></div>
<p>Each tablet for oral administration contains 25 mg of benzphetamine hydrochloride.</p>
<p>In addition, both strengths contain calcium stearate, corn starch, D&amp;C Red #30 Aluminum Lake and sorbitol.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Benzphetamine hydrochloride is a sympathomimetic amine with pharmacologic activity similar to the prototype drugs of this class used in <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, the amphetamines. Actions include central nervous system stimulation and elevation of blood pressure. <span class="product-label-link" type="condition" conceptid="4052861" conceptname="Tachyphylaxis">Tachyphylaxis</span> and tolerance have been demonstrated with all drugs of this class in which these phenomena have been looked for.</p>
<p>Drugs of this class used in <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span> are commonly known as "<span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectics</span>" or "anorexigenics". It has not been established, however, that the action of such drugs in treating <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span> is primarily one of <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">appetite suppression</span>. Other central nervous system actions, or metabolic effects, may be involved.</p>
<p>Adult obese subjects instructed in dietary management and treated with "<span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectic</span>" drugs, lose more weight on the average than those treated with placebo and diet, as determined in relatively short-term clinical trials.</p>
<p>The magnitude of increased <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> of drug-treated patients over placebo-treated patients is only a fraction of a pound a week. The rate of <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> is the greatest in the first weeks of therapy for both drug and placebo subjects and tends to decrease in succeeding weeks. The possible origins of the increased <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> due to the various drug effects are not established. The amount of <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> associated with the use of an "<span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectic</span>" drug varies from trial to trial, and the increased <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> appears to be related in part to variables other than the drug prescribed, such as the physician-investigator, the population treated, and the diet prescribed. Studies do not permit conclusions as to the relative importance of the drug and non-drug factors on <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>.</p>
<p>The natural history of <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span> is measured in years, whereas the studies cited are restricted to a few weeks duration; thus, the total impact of drug-induced <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> over that of diet alone must be considered to be clinically limited.</p>
<p>Pharmacokinetic data in humans are not available.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s3"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First"><span class="Bold">Regimexâ„¢</span> tablets are indicated in the management of exogenous <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span> as a short term (a few weeks) adjunct in a regimen of weight reduction based on caloric restriction in patients with an initial body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> index (BMI) of 30 kg/m<span class="Sup">2</span> or higher who have not responded to appropriate weight reducing regimen (diet and/or exercise) alone.  Below is a chart of Body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">Mass</span> Index (BMI) based on various heights and weights.  BMI is calculated by taking the patient's weight, in kilograms (kg), divided by the patient's height, in meters (m), squared.  Metric conversions are as follows:  pounds Ã· 2.2 = kg; inches Ã— 0.0254 = meters.  The limited usefulness of agents of this class (See <span class="Bold"><a href="#s2">CLINICAL PHARMACOLOGY</a></span>) should be weighed against possible risks inherent in their use such as those described below.</p>
<a name="t1"></a><table width="395">
<caption><span>BODY <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">MASS</span> INDEX (BMI), kg/m<span class="Sup">2</span></span></caption>
<col width="18.0%">
<col width="12.7%">
<col width="13.7%">
<col width="13.9%">
<col width="13.9%">
<col width="13.9%">
<col width="13.9%">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Toprule" align="center" valign="top"><span class="Bold">Weight</span></td>
<td class="Rrule" align="center" colspan="6" valign="top"><span class="Bold">Height (feet, inches)</span></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" valign="top"><span class="Bold">(pounds)</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">5'0"</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">5'3"</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">5'6"</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">5'9"</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">6'0"</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">6'3"</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">140</td>
<td class="Rrule" align="center" valign="top">27</td>
<td class="Botrule" align="center" valign="top">25</td>
<td align="center" valign="top">23</td>
<td align="center" valign="top">21</td>
<td align="center" valign="top">19</td>
<td class="Rrule" align="center" valign="top">18</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">150</td>
<td class="Botrule Rrule" align="center" valign="top">29</td>
<td class="Rrule" align="center" valign="top">27</td>
<td align="center" valign="top">24</td>
<td align="center" valign="top">22</td>
<td align="center" valign="top">20</td>
<td class="Rrule" align="center" valign="top">19</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">160</td>
<td class="Rrule" align="center" valign="top">31</td>
<td class="Botrule Rrule" align="center" valign="top">28</td>
<td class="Botrule" align="center" valign="top">26</td>
<td align="center" valign="top">24</td>
<td align="center" valign="top">22</td>
<td class="Rrule" align="center" valign="top">20</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">170</td>
<td align="center" valign="top">33</td>
<td class="Rrule" align="center" valign="top">30</td>
<td class="Rrule" align="center" valign="top">28</td>
<td class="Botrule" align="center" valign="top">25</td>
<td align="center" valign="top">23</td>
<td class="Rrule" align="center" valign="top">21</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">180</td>
<td align="center" valign="top">35</td>
<td class="Rrule" align="center" valign="top">32</td>
<td class="Botrule Rrule" align="center" valign="top">29</td>
<td class="Rrule" align="center" valign="top">27</td>
<td align="center" valign="top">25</td>
<td class="Rrule" align="center" valign="top">23</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">190</td>
<td align="center" valign="top">37</td>
<td align="center" valign="top">34</td>
<td class="Rrule" align="center" valign="top">31</td>
<td class="Botrule Rrule" align="center" valign="top">28</td>
<td class="Botrule" align="center" valign="top">26</td>
<td class="Rrule" align="center" valign="top">24</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">200</td>
<td align="center" valign="top">39</td>
<td align="center" valign="top">36</td>
<td align="center" valign="top">32</td>
<td class="Rrule" align="center" valign="top">30</td>
<td class="Rrule" align="center" valign="top">27</td>
<td class="Rrule" align="center" valign="top">25</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">210</td>
<td align="center" valign="top">41</td>
<td align="center" valign="top">37</td>
<td align="center" valign="top">34</td>
<td class="Rrule" align="center" valign="top">31</td>
<td class="Botrule Rrule" align="center" valign="top">29</td>
<td class="Botrule Rrule" align="center" valign="top">26</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">220</td>
<td align="center" valign="top">43</td>
<td align="center" valign="top">39</td>
<td align="center" valign="top">36</td>
<td align="center" valign="top">33</td>
<td class="Rrule" align="center" valign="top">30</td>
<td class="Rrule" align="center" valign="top">28</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">230</td>
<td align="center" valign="top">45</td>
<td align="center" valign="top">41</td>
<td align="center" valign="top">37</td>
<td align="center" valign="top">34</td>
<td class="Rrule" align="center" valign="top">31</td>
<td class="Botrule Rrule" align="center" valign="top">29</td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top">240</td>
<td align="center" valign="top">47</td>
<td align="center" valign="top">43</td>
<td align="center" valign="top">39</td>
<td align="center" valign="top">36</td>
<td align="center" valign="top">33</td>
<td class="Rrule" align="center" valign="top">30</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top">250</td>
<td class="Botrule" align="center" valign="top">49</td>
<td class="Botrule" align="center" valign="top">44</td>
<td class="Botrule" align="center" valign="top">40</td>
<td class="Botrule" align="center" valign="top">37</td>
<td class="Botrule" align="center" valign="top">34</td>
<td class="Botrule Rrule" align="center" valign="top">31</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Regimexâ„¢</span> tablets are indicated for use as monotherapy only.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s4"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><span class="Bold">Regimexâ„¢</span> tablets are contraindicated in patients with advanced <span class="product-label-link" type="condition" conceptid="4103842" conceptname="Arteriosclerosis">arteriosclerosis</span>, symptomatic cardiovascular disease, moderate to severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> or idiosyncrasy to sympathomimetic amines, and <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. Benzphetamine should not be given to patients who are in an <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> state or who have a history of drug abuse.</p>
<p>Hypertensive crises have resulted when sympathomimetic amines have been used concomitantly or within 14 days following use of monoamine oxidase inhibitors. <span class="Bold">Regimexâ„¢</span> tablets should not be used concomitantly with other CNS stimulants.</p>
<p><span class="Bold">Regimexâ„¢</span> tablets may cause fetal harm when administered to a pregnant woman. Amphetamines have been shown to be teratogenic and embryotoxic in mammals at high multiples of the human dose. <span class="Bold">Regimexâ„¢</span> tablets are contraindicated in women who are or may become pregnant. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s5"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="Bold"><span class="Bold">Regimexâ„¢</span> tablets should not be used in combination with other <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectic</span> agents, including prescribed drugs, over-the-counter preparations and herbal products.</span></p>
<p>In a case-control epidemiological study, the use of <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectic</span> agents was associated with an increased risk of developing <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span>, a rare, but often fatal disorder.  The use of <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectic</span> agents for longer than three months was associated with a 23-fold increase in the risk of developing <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span>.  Increased risk of <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span> with repeated courses of therapy cannot be excluded.  It should be noted that benzphetamine was not specifically studied in this case-control study.</p>
<p>The onset or aggravation of <span class="product-label-link" type="condition" conceptid="4263848" conceptname="Dyspnea on exertion">exertional dyspnea</span>, or unexplained symptoms of <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, or lower extremity <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> suggest the possibility of occurrence of <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span>.  Under these circumstances, <span class="Bold">Regimexâ„¢</span> tablets should be immediately discontinued, and the patient should be evaluated for the possible presence of <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span>.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4281749" conceptname="Heart valve disorder">Valvular heart disease</span> associated with the use of some <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectic</span> agents such as fenfluramine and dexfenfluramine has been reported. Possible contributing factors include use for extended periods of time, higher than recommended dose, and/or use in combination with other <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectic</span> drugs. However, no cases of this valvulopathy have been reported when benzphetamine has been used alone.</span></p>
<p>The potential risk of possible serious adverse effects such as <span class="product-label-link" type="condition" conceptid="4281749" conceptname="Heart valve disorder">valvular heart disease</span> and <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span> should be assessed carefully against the potential benefit of <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>. Baseline cardiac evaluation should be considered to detect pre-existing <span class="product-label-link" type="condition" conceptid="4281749" conceptname="Heart valve disorder">valvular heart diseases</span> or <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span> prior to initiation of benzphetamine treatment. <span class="Bold">Regimexâ„¢</span> tablets are not recommended in patients with known <span class="product-label-link" type="condition" conceptid="316822" conceptname="Heart murmur">heart murmur</span> or <span class="product-label-link" type="condition" conceptid="4281749" conceptname="Heart valve disorder">valvular heart disease</span>. Echocardiogram during and after treatment could be useful for detecting any valvular disorders which may occur. To limit unwarranted exposure and risks, treatment with <span class="Bold">Regimexâ„¢</span> tablets should be continued only if the patient has satisfactory <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> within the first 4 weeks of treatment (i.e., <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> of at least 4 pounds, or as determined by the physician and patient).</p>
<p>When tolerance to the <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectic</span> effect develops, the recommended dose should not be exceeded in an attempt to increase the effect; rather, the drug should be discontinued.</p>
<p><span class="Bold">Regimexâ„¢</span> tablets are not recommended for severely hypertensive patients or for patients with symptomatic cardiovascular disease including <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>.</p>
<p><span class="Bold">Regimexâ„¢</span> tablets are not recommended for patients who used any <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectic</span> agents within the prior year.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s6"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s6.1"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">Insulin requirements in <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus may be altered in association with use of anorexigenic drugs and the concomitant dietary restrictions.</p>
<p>Psychological disturbances have been reported in patients who receive an <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectic</span> agent together with a restrictive dietary regime. </p>
<p>Caution is to be exercised in prescribing amphetamines for patients with even mild <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s7"></a><a name="section-6.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Amphetamines may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle; the patient should therefore be cautioned accordingly.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s8"></a><a name="section-6.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Efficacy of <span class="Bold">Regimexâ„¢</span> tablets in combination with other <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectic</span> agents has not been studied and the combined use may have the potential for serious cardiac problems.</p>
<p>Hypertensive crises have resulted when sympathomimetic amines have been used concomitantly or within 14 days following use of monoamine oxidase inhibitors. <span class="Bold">Regimexâ„¢</span> tablets should not be used concomitantly with other CNS stimulants.</p>
<p>Amphetamines may decrease the hypotensive effect of antihypertensives. Amphetamines may enhance the effects of tricyclic antidepressants.</p>
<p>Urinary alkalinizing agents increase blood levels and decrease excretion of amphetamines. Urinary acidifying agents decrease blood levels and increase excretion of amphetamines.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s9"></a><a name="section-6.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Animal studies to evaluate the potential for carcinogenesis, mutagenesis or impairment of fertility have not been performed.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s10"></a><a name="section-6.5"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s10.1"></a><a name="section-6.5.1"></a><p></p>
<h3>Pregnancy Category X</h3>
<p class="First">(see <span class="Bold"><a href="#s4">CONTRAINDICATIONS</a></span> section).</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s11"></a><a name="section-6.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Amphetamines are excreted in human milk. Mothers taking amphetamines should be advised to refrain from nursing.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s12"></a><a name="section-6.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
<p>Use of benzphetamine hydrochloride is not recommended in individuals under 12 years of age.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s13"></a><a name="section-6.8"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of benzphetamine hydrochloride tablets did not include sufficient numbers of subjects aged 65 and over to establish safety and efficacy in this population. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s14"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The following have been associated with the use of benzphetamine hydrochloride:</p>
<p><span class="Italics">Cardiovascular</span></p>
<p><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitation</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, elevation of blood pressure.</p>
<p>There have been isolated reports of <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span> and ischemic cardiac events associated with chronic amphetamine use.</p>
<p><span class="product-label-link" type="condition" conceptid="4281749" conceptname="Heart valve disorder">Valvular heart disease</span> associated with the use of some <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectic</span> agents such as fenfluramine and dexfenfluramine, both independently and especially when used in combination with other <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectic</span> drugs, have been reported. However, no cases of this valvulopathy have been reported when <span class="Bold">Regimexâ„¢</span> tablets have been used alone.</p>
<p><span class="Italics">CNS</span></p>
<p>Overstimulation, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>; rarely, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic episodes</span> at recommended doses; <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> following withdrawal of the drug.</p>
<p><span class="Italics">Gastrointestinal</span></p>
<p>Dryness of the mouth, unpleasant taste, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, other <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal disturbances</span>.</p>
<p><span class="Italics">Allergic</span></p>
<p><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span> and other <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> involving the skin.</p>
<p><span class="Italics">Endocrine</span></p>
<p>Changes in libido.</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="s15"></a><a name="section-8"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First">Benzphetamine is a controlled substance under the Controlled Substance Act by the Drug Enforcement Administration and has been assigned to Schedule III.</p>
<p>Benzphetamine hydrochloride is related chemically and pharmacologically to the amphetamines. Amphetamines and related stimulant drugs have been extensively abused, and the possibility of abuse of <span class="Bold">Regimexâ„¢</span> tablets should be kept in mind when evaluating the desirability of including a drug as part of a weight reduction program. Abuse of amphetamines and related drugs may be associated with intense psychological <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and severe social dysfunction. There are reports of patients who have increased the dosage to many times that recommended. Abrupt cessation following prolonged high dosage administration results in extreme <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> and mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>; changes are also noted on the sleep EEG. Manifestations of chronic <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> with <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectic</span> drugs include severe dermatoses, marked <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span>, and <span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">personality changes</span>. The most severe manifestation of chronic <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> is <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, often clinically indistinguishable from <span class="product-label-link" type="condition" conceptid="435783" conceptname="Schizophrenia">schizophrenia</span>.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s16"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s16.1"></a><a name="section-9.1"></a><p></p>
<h2>Manifestations of Overdosage</h2>
<p class="First">Acute overdosage with amphetamines may result in <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, assaultiveness and panic states. <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span> and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> usually follow the central stimulation. Cardiovascular effects include <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>. <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal symptoms</span> include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>. <span class="product-label-link" type="condition" conceptid="4260205" conceptname="Hyperpyrexia">Hyperpyrexia</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> have been reported and can lead to a number of associated complications. Fatal <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> is usually preceded by <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s16.2"></a><a name="section-9.2"></a><p></p>
<h2>Treatment of Overdosage</h2>
<p class="First">(See <span class="Bold"><a href="#s5">WARNINGS</a></span>)-Information concerning the effects of overdosage with <span class="Bold">Regimexâ„¢</span> tablets is extremely limited. The following is based on experience with other anorexiants.</p>
<p>Management of acute amphetamine <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> is largely symptomatic and includes sedation with a barbiturate. If <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> is marked, the use of a nitrite or rapidly acting alpha receptor blocking agent should be considered. Experience with hemodialysis or peritoneal dialysis is inadequate to permit recommendations in this regard.</p>
<p>Acidification of the urine increases amphetamine excretion.</p>
<p>The oral LD<span class="Sub">50</span> is 174 mg/kg in mice and 104 mg/kg in rats. The intraperitoneal LD<span class="Sub">50</span> in mice is 153 mg/kg.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s17"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Dosage should be individualized according to the response of the patient. The suggested dosage ranges from 25 to 50 mg one to three times daily. Treatment should begin with 25 to 50 mg once daily with subsequent increase in individual dose or frequency according to response. A single daily dose is preferably given in mid-morning or mid-afternoon, according to the patient's eating habits. In an occasional patient it may be desirable to avoid late afternoon administration. Use of benzphetamine hydrochloride is not recommended in individuals under 12 years of age.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s18"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><span class="Bold">Regimexâ„¢</span> tablets are supplied as follows: <span class="Bold">25 mg:</span>  Pink, round tablet, debossed â€œEXâ€? on one side and â€œ25â€? on the other side in bottles of 100 tablets,
NDC 66992-399-10.</p>
<p>Store at controlled room temperature 20Â° to 25Â°C (68Â° to 77Â°F) [See USP Controlled Room Temperature].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<p class="First">Manufactured by:<br><span class="Bold">Mikart, Inc.</span><br>Atlanta, GA 30318</p>
<p>Distributed by:<br>WraSer Pharmaceuticals<br>Ridgeland, MS 39157</p>
<p>Code 1025Z00</p>
<p>Rev. 09/12</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">NDC 66992-399-10 Â Â  Â  Â  Â  Â  Â  Â  Â  <span class="Bold">100 Tablets</span></p>
<p><span class="Bold Italics">Regimex â„¢</span></p>
<p><span class="Bold">Benzphetamine CIII<br>Hydrochloride Tablets</span></p>
<p><span class="Bold">Start Your Regimen<br> with Regimexâ„¢</span></p>
<p>25 mg Â Â Â Â Â Â Â Â <span class="Bold">Rx Only</span></p>
<div class="Figure"><img alt="100 count bottle label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1a5d7233-4453-42a5-8144-a4276db39660&amp;name=1a5d7233-4453-42a5-8144-a4276db39660-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>REGIMEXÂ 		
					</strong><br><span class="contentTableReg">benzphetamine hydrochloride tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:66992-399</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIIIÂ Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>BENZPHETAMINE HYDROCHLORIDE</strong> (BENZPHETAMINE) </td>
<td class="formItem">BENZPHETAMINE HYDROCHLORIDE</td>
<td class="formItem">25Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C RED NO. 30</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SORBITOL</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PINK</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">5mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">EX;25</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:66992-399-10</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA090473</td>
<td class="formItem">02/01/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Wraser Pharmaceuticals
							(121828334)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 3/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>1a5d7233-4453-42a5-8144-a4276db39660</div>
<div>Set id: 1a5d7233-4453-42a5-8144-a4276db39660</div>
<div>Version: 1</div>
<div>Effective Time: 20130313</div>
</div>
</div>Â <div class="DistributorName">Wraser Pharmaceuticals</div></p>
</body></html>
